Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Clin Endocrinol (Oxf). 2011 Jun;74(6):694–698. doi: 10.1111/j.1365-2265.2011.04021.x

Figure 1.

Figure 1

HPLC profiles of circulating PTH molecular forms, obtained with Whole PTH (—) and total PTH (----) assays, are illustrated after the 4th surgery (A) and before (B) and after 5th surgery (C) for the first patient and during Cinacalcet HCl therapy for the second patient (D). The regions of elution of hPTH(1-84), NT-N PTH and non(1-84) PTH fragments are indicated at the top (A, B). NT-N PTH overexpression is seen in B and D where it represents 82.2% and 51.9% of W-PTH immunoreactivity respectively. The different elution positions observed in A, B, C vs D are related to the use of different HPLC columns.